Evidence map›Paper›PMID 33215234›Full record

ArticleWiener klinische Wochenschrift2021

Austrian recommendations for the management of essential thrombocythemia.

Veronika Buxhofer-Ausch, Sonja Heibl, Thamer Sliwa, Christine Beham-Schmid, Dominik Wolf, Klaus Geissler, Maria Theresa Krauth, Peter Krippl, Andreas Petzer, Albert Wölfler and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Acetylsalicylic acid in essential thrombocythemia.Wiener klinische Wochenschrift · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Veronika Buxhofer-AuschDepartment of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Fadingerstraße 1, 4020, Linz, Austria. veronika.buxhofer-ausch@ordensklinikum.at.ORCID http://orcid.org/0000-0002-7369-9700
Sonja HeiblDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Thamer Sliwa3rd Medical Department, Hanusch Hospital, Vienna, Austria.
Christine Beham-SchmidInstitute of Pathology, Medical University Graz, Graz, Austria.
Dominik WolfDivision of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria.
Klaus Geissler5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria.
Maria Theresa KrauthDepartment of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.
Peter KripplDepartment of Internal Medicine with Hematology and Oncology, Steiermärkische Krankenanstaltengesellschaft m. b. H. Krankenhausverbund Feldbach-Fürstenfeld, Fürstenfeld, Austria.
Andreas PetzerMedizinische Fakultät, Johannes Kepler Universität Linz, Altenberger Straße 69, 4040, Linz, Austria.
Albert WölflerDivision of Hematology, Medical University of Graz, Graz, Austria.
Thomas Melchardt3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria.
Heinz GisslingerDepartment of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.
Johannes Kepler University of Linz · ATMedical University of Graz · ATMedical University of Vienna · ATHanusch Hospital · ATInnsbruck Medical University · ATKlinik Hietzing · ATKlinikum Wels-Grieskirchen · ATParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the World Health Organization (WHO) classification, essential (primary) thrombocythemia (ET) is one of several Bcr-Abl negative chronic myeloproliferative neoplasms (MPN). The classical term MPN covers the subcategories of MPN: ET, polycythemia vera (PV), primary myelofibrosis (PMF), and prefibrotic PMF (pPMF). ET is marked by clonal proliferation of hematopoietic stem cells, leading to a chronic overproduction of platelets. At the molecular level a JAK2 (Janus Kinase 2), calreticulin, or MPL mutation is found in the majority of patients. Typical ongoing complications of the disease include thrombosis and hemorrhage. Primary and secondary prevention of these complications can be achieved with platelet function inhibitors and various cytoreductive drugs including anagrelide, hydroxyurea and interferon. After a long follow up, in a minority of ET patients the disease transforms into post-ET myelofibrosis or secondary leukemia. Overall, life expectancy with ET is only slightly decreased.

Indexed as

Myeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialAustriaHumansMutationEssential thrombocythemiaManagement recommendationsMyeloproliferative neoplasmsRisk stratificationTreatment

Identifiers

PMID33215234
OpenAlexW3105975490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.